Development and validation of an interpretable prediction model using spatial patterns of tumor-infiltrating lymphocytes in H&E-stained whole-slide images for immune subtyping of lung adenocarcinoma - Top-Institutions - MDSpire

Development and validation of an interpretable prediction model using spatial patterns of tumor-infiltrating lymphocytes in H&E-stained whole-slide images for immune subtyping of lung adenocarcinoma

  • By

  • Xia Li

  • Hai-Zhen Qin

  • Jing-Yu Wei

  • Kang-Lai Wei

  • Zhao-Quan Huang

  • May 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Pathology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Pathology

  • #3

    Gustave Roussy
    Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology
    • Pathology

  • #4

    The Cancer Genome Atlas
    The Cancer Genome Atlas

    N/A, N/A

    Key Differentiators

    • Genomics
    • Pathology

  • #5

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Oncology
    • Pathology

Original Source(s)

Development and validation of an interpretable prediction model using spatial patterns of tumor-infiltrating lymphocytes in H&E-stained whole-slide images for immune subtyping of lung adenocarcinoma

  • by Xia Li, Hai-Zhen Qin, Jing-Yu Wei, Kang-Lai Wei, Zhao-Quan Huang

  • May 8, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients